Search research articles
Contact Us
Filters
Showing results (641-650 of 674) with videos related to
Page
of 68
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2018
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Cancer Immunology Research
|
June 17, 2017
Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity
Xiuli Zhang, Samuel Kim, Jasreet Hundal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2018
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With
Shukui Qin, Jin Li, Liwei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Annals of Neurology
|
August 23, 2024
Population-Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis
Simon Witzel, André Huss, Gabriele Nagel, et al.
Nature Communications
|
May 3, 2020
Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression
Jessica M Silva-Fisher, Ha X Dang, Nicole M White, et al.
The Lancet. Oncology
|
April 9, 2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, et al.
Arxiv
|
July 3, 2026
pVACtools v6: A comprehensive suite for neoantigen prediction, visualization, and therapy design
My H Hoang, Susanna Kiwala, Megan Richters, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Page
of 68
Search research articles
Search
Showing results (641-650 of 674) with videos related to
Sort By:
Page
of 68
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2018
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Cancer Immunology Research
|
June 17, 2017
Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity
Xiuli Zhang, Samuel Kim, Jasreet Hundal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2018
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With
Shukui Qin, Jin Li, Liwei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Annals of Neurology
|
August 23, 2024
Population-Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis
Simon Witzel, André Huss, Gabriele Nagel, et al.
Nature Communications
|
May 3, 2020
Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression
Jessica M Silva-Fisher, Ha X Dang, Nicole M White, et al.
The Lancet. Oncology
|
April 9, 2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, et al.
Arxiv
|
July 3, 2026
pVACtools v6: A comprehensive suite for neoantigen prediction, visualization, and therapy design
My H Hoang, Susanna Kiwala, Megan Richters, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Page
of 68